Robbie G. Majzner

May 15, 2024 | nature.com | Sean A. Yamada-Hunter |Brianna J. McIntosh |Frank Lin |Amaury Leruste |Zinaida Good |Calvin J Kuo | +6 more

AbstractAdoptively transferred T cells and agents designed to block the CD47–SIRPα axis are promising cancer therapeutics that activate distinct arms of the immune system1,2. Here we administered anti-CD47 antibodies in combination with adoptively transferred T cells with the goal of enhancing antitumour efficacy but observed abrogated therapeutic benefit due to rapid macrophage-mediated clearance of T cells expressing chimeric antigen receptors (CARs) or engineered T cell receptors.

Nov 8, 2023 | nature.com | Caleb A Lareau |Yajie Yin |Katie Maurer |Katalin Sandor |Bence Daniel |Jose Sanz Peña | +20 more

AbstractCell therapies have yielded durable clinical benefits for patients with cancer, but the risks associated with the development of therapies from manipulated human cells are understudied. For example, we lack a comprehensive understanding of the mechanisms of toxicities observed in patients receiving T cell therapies, including recent reports of encephalitis caused by reactivation of human herpesvirus 6 (HHV-6)1.

Apr 6, 2023 | nature.com | Karin Straathof |Tom Davidson |Kara L. Davis |Juliane Gust |Michael Lim |Robbie G. Majzner | +6 more

AbstractCancer immunotherapies have unique toxicities. Establishment of grading scales and standardized grade-based treatment algorithms for toxicity syndromes can improve the safety of these treatments, as observed for cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS) in patients with B cell malignancies treated with chimeric antigen receptor (CAR) T cell therapy.

Apr 5, 2023 | social.cn1699.com | Robbie G. Majzner

Source/DisclosuresPublished by: Source: Del Bufalo F, et al. N Engl J Med. 2023;doi:10.1056/NEJMoa2210859. Disclosures: Locatelli and Longo report no relevant financial disclosures. Yeku reports grants or personal fees from Ascendis Pharma A/S, Avenge Bio, Celldex Therapeutics, Department of Defense, Duality Biologics, GIMV NV, hC Bioscience, Immunocore Limited, Merck Sharp & Dohme, Pionyr Immunotherapeutics, ProfoundBio and TigaTX outside the submitted work.